OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...
Pharmaceutical Technology on MSN2d
Opko and Entera focus on oral care for obesity and metabolic disordersOpko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...
This new treatment combines OPKO's long-acting oxyntomodulin analog, OPK-88006, with Entera's N-Tab™ technology and shows promising data from preclinical studies. The companies plan to submit an ...
The program combines OPKO's long-acting oxyntomodulin analog or OPK-88006 with Entera's proprietary N-Tab technology, and promising pharmacodynamic data has already been reported. The goal of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback